Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
+$0.09 today
- Market cap
- $595.91M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
Volume 0.88M
Average 1.07M
IMMX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Immix Biopharma, Inc.NASDAQ: IMMX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $130.77K rose 121.0% year over year, behind the +189.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 44.3% from the prior quarter. Over 3 fiscal years it compounded at +454.8% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +121.0% toward the trailing-twelve-month pace of +189.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 364.5K USD
- Year-over-year change
- +215.9%
- 4-year CAGR
- +248.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 364.5K | +215.9% |
| FY2024 | 2024-12-31 | 115.39K | +2010.2% |
| FY2023 | 2023-12-31 | 5.47K | +156.1% |
| FY2022 | 2022-12-31 | 2.14K | -13.5% |
| FY2021 | 2021-12-31 | 2.47K | — |
Depreciation & Amortization vs competitors
How IMMX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +189.3% is the highest of 10, against a peer median of +0.0%.
- Over three fiscal years its annual growth of +454.8% compares with a peer median of +11.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $15.87M USD | -14.3% | +20.4% | 2.3% | |
| LTM Jun 2026 | $10M USD | +0.0% | +18.6% | 8.5% | |
| LTM Mar 2026 | $6.94M USD | -7.1% | -22.5% | 4.4% | |
| LTM Sep 2026 | $3.73M USD | +10.4% | +5.3% | 3333.9% | |
| FY2025 | A$2.39M AUD | +5.6% | +5.0% | 47.4% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥1.54M CNY | — | -76.2% | — |
| LTM Mar 2026 | $1.17M USD | +120.2% | +56.5% | 222.3% | |
| FY2025 | €1.07M EUR | -2.5% | +30.3% | — | |
| LTM Mar 2026 | $1.03M USD | -39.0% | -38.3% | 2.9% | |
| LTM Mar 2026 | $436.09K USD | +189.3% | +454.8% | — | |
| LTM Mar 2026 | $158K USD | +4.6% | +29.7% | — | |
| Peer median (excluding IMMX) | — | +0.0% | +11.9% | 8.5% | |
Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.38M) | (8.23M) | (15.6M) | (21.61M) | (29.44M) |
| Depreciation & Amortization | 2.47K | 2.14K | 5.47K | 115.39K | 364.5K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 218.98K | 624.07K | 2.57M | 3.02M | 2.44M |
| Change in Working Capital | (391.04K) | 195.21K | 1.65M | 3.97M | 2.7M |
| Accounts Receivables | 97.67K | (236.38K) | (893.4K) | (971.53K) | 2.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (106.06K) | 1.13M | 2.43M | 4.4M | 1.03M |
| Other Working Capital | (382.64K) | (700.15K) | 111.84K | 537.2K | (384.74K) |
| Other Non-Cash Items | 22.96M | 0 | 0 | 2.94M | 0 |
| Operating Cash Flow | (1.59M) | (7.41M) | (11.37M) | (14.6M) | (23.93M) |
| Capital Expenditures | (802) | 3 | (52.09K) | (1.18M) | (732.93K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (6.48M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (802) | 0 | (52.09K) | (1.18M) | (7.21M) |
| Debt Repayment | 200K | (50K) | 0 | 0 | 0 |
| Common Stock Issued | 18.65M | 3.39M | 15.7M | 15.95M | 107.39M |
| Common Stock Repurchased | 0 | (99.96K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (6.72K) | (232K) | 0 | 0 |
| Financing Cash Flow | 18.85M | 3.23M | 15.46M | 15.95M | 107.39M |
| Effect of Forex Changes | (5.43K) | (31.52K) | 33.09K | (3.62K) | 3.84K |
| Net Change in Cash | 17.25M | (4.21M) | 4.07M | 172.16K | 76.25M |
| Free Cash Flow | (1.59M) | (7.41M) | (11.42M) | (15.77M) | (24.66M) |
Immix Biopharma, Inc.
NASDAQ:IMMX
Intrinsic Alpha fair value
Locked
Current Price
$7.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.